Re: Trace Visit and Beckman device at DNAP:
"Busting at the seams" would seem to indicate either/or:
1. More work than can be handled.
2. Individual projects requiring "space".
3. Staff has put on weight.
In the light of DNAG quadrupling device thru-put, and recent decisions and actions to acquire Trace and portion of Biofrontera, it sounds like "0ption 3 Staff has put on weight" is not viable with all the additional work the other options would seem to indicate is anticipated.
The recent complaints about management doing nothing to bolster the share price are hot air. As shareholders, and hence owning any portion of DNAG, the management sees thier portionate share of DNAG decrease each time a share is converted to operating capital. I think they are as aware as we investors are, that a simple increase in the share price reduces the necessary dillution, preserving the value of our percentage ownership. To argue otherwise is to say management favors giving up any reward for thier efforts. That doesn't make any sense to me. Even if they issue more shares in lieu of salary or as bonuses those shares represent a diminishing return and would do more to reduce the pps on the market, requiring more dillution and lessening the value of the company as a whole.
Easy had commented on management and was leaning toward a "them bums" label. I think we all can see that the prospects and opportunities for DNAG have expanded exponentially for us all since the troika arrived. Yes the share price has gone down. You now own less of a greater whole. That is evident from all the filings. Shares are being sold to acomplish this expansion and further development. If the share price was highter, less "division" of the company would occur. Remember back to DNAP under Doctor Frudakis as CEO. How did the doors stay open. A trail of form 4 filings tell the story. If we didn't have the management team we have now, where would we be instead?
Would Doctor Frudakis have found the financing? La Jolla Cove would put up money? A private placement, but just to keep the doors open status quo? I don't think we could have survived to this point under Doctor Frudakis's management. I truly believe he is better toiling in the lab 100% than in the boardroom 100%.
What does keep Doctor Frudakis in the lab and working on what makes DNAP unique. The management team that is guiding DNAG. Guiding DNAG, and Trace and having a strong voice in Biofrontera's activities. Putting together addittional academic support besides that of Dr. Shreiver and Mckeigue. There is so much happening that we can't all keep track of the sum total. DNAG is growing, and each day we keep the doors open, we become a greater and stronger whole. We trade a percentage of ownership for that priveledge. Can we survive to bring one of the projects to fruition? Beth Israel was willing to allow DNAP / DNAG an opportunity. The folks at Trace allowed thier company to be bought out by DNAG. Affimetrix is depending on DNAG for some work. Maybe I have 3D glasses on but there is a synergy developing that may be beyond my wildest dreams.
Meanwhile, the price per share decreases and each sale of shares at this low pps causes more proportionate dillution. Time is the enemy and each day without significant revenue, or firm contract promising the same is hurtful for us all, investors and management alike. To propose that management is unaware or uncaring of this situation is simply a false statement by some, or a misinterpretation of the business "facts of life" by others. Given posting histories available here, you can apply the appropriate labels, and determine for yourselves the weight to give to the opinions expressed, by me, or any others.
I'm long. I'm still here. I will be here. I can't bear to think of missing a single chapter.
Stakddek
